Logo image of AMYT

AMRYT PHARMA PLC - SPNR ADR (AMYT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:AMYT - US03217L1061 - ADR

14.7 USD
+0.01 (+0.07%)
Last: 4/11/2023, 8:09:37 PM
14.7 USD
0 (0%)
After Hours: 4/11/2023, 8:09:37 PM
Fundamental Rating

0

Taking everything into account, AMYT scores 0 out of 10 in our fundamental rating. AMYT was compared to 190 industry peers in the Pharmaceuticals industry. AMYT has a bad profitability rating. Also its financial health evaluation is rather negative. AMYT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

AMYT Yearly Net Income VS EBIT VS OCF VS FCFAMYT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 0 20M -20M -40M -60M -80M -100M

1.2 Ratios

  • The profitability ratios for AMYT are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AMYT Yearly ROA, ROE, ROICAMYT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 0 200 400 600 800

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for AMYT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AMYT Yearly Profit, Operating, Gross MarginsAMYT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 0 -200 -400

More info and screens

0

2. Health

2.1 Basic Checks

  • AMYT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, AMYT has more shares outstanding
  • The debt/assets ratio for AMYT is higher compared to a year ago.
AMYT Yearly Shares OutstandingAMYT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 50M 100M 150M
AMYT Yearly Total Debt VS Total AssetsAMYT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 100M 200M 300M 400M 500M

2.2 Solvency

Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC9.16%
AMYT Yearly LT Debt VS Equity VS FCFAMYT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 0 50M 100M 150M

2.3 Liquidity

Industry RankSector Rank
Current Ratio N/A
Quick Ratio N/A
AMYT Yearly Current Assets VS Current LiabilitesAMYT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 50M 100M 150M 200M

More info and screens

0

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AMYT Yearly Revenue VS EstimatesAMYT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
AMYT Yearly EPS VS EstimatesAMYT Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 0.5 1 1.5 2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

Industry RankSector Rank
PE N/A
Fwd PE N/A
AMYT Price Earnings VS Forward Price EarningsAMYT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AMYT Per share dataAMYT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for AMYT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMRYT PHARMA PLC - SPNR ADR / AMYT FAQ

What is the ChartMill fundamental rating of AMRYT PHARMA PLC - SPNR ADR (AMYT) stock?

ChartMill assigns a fundamental rating of 0 / 10 to AMYT.


Can you provide the valuation status for AMRYT PHARMA PLC - SPNR ADR?

ChartMill assigns a valuation rating of 0 / 10 to AMRYT PHARMA PLC - SPNR ADR (AMYT). This can be considered as Overvalued.


How profitable is AMRYT PHARMA PLC - SPNR ADR (AMYT) stock?

AMRYT PHARMA PLC - SPNR ADR (AMYT) has a profitability rating of 0 / 10.


What is the financial health of AMRYT PHARMA PLC - SPNR ADR (AMYT) stock?

The financial health rating of AMRYT PHARMA PLC - SPNR ADR (AMYT) is 0 / 10.